Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INDUSTRY VETERAN RAMI LEVIN, MBA APPOINTED AS PRESIDENT & CHIEF EXECUTIVE OFFICER HOUSTON, TX / ACCESS NEWSWIRE / DECEMBER 17, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED JOHN CLIMACO HAS STEPPED DOWN AS CHIEF EXECUTIVE OFFICER OF CNS PHARMACEUTICALS AND RAMI LEVIN, MBA, HAS BEEN APPOINTED AS PRESIDENT & CHIEF EXECUTIVE OFFICER. MR. LEVIN BRINGS NEARLY 30 YEARS OF GLOBAL LEADERSHIP EXPERIENCE ACROSS ONCOLOGY, NEUROLOGY, RARE DISEASES, ENDOCRINOLOGY, AND CELL AND GENE THERAPY, WITH A PROVEN TRACK RECORD OF SCALING ORGANIZATIONS, ADVANCING LATE-STAGE CLINICAL PROGRAMS, AND DRIVING TRANSFORMATIVE VALUE CREATION.

CNS PHARMACEUTICALS ANNOUNCES CEO TRANSITION

CASH EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2026 COMPANY FOCUSED ON ADVANCING NEXT-GENERATION ANTI-CANCER THERAPIES DERIVED FROM WELL-ESTABLISHED DRUG CLASSES, NOW ENGINEERED TO CROSS THE BLOOD-BRAIN BARRIER, POTENTIALLY ENHANCING EFFICACY FOR PATIENTS LEAD PROGRAM, TPI 287, PROGRESSING TOWARD PHASE 2 STUDY FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM), ONE OF THE MOST AGGRESSIVE TYPES OF BRAIN CANCER, WITH A MEDIAN SURVIVAL OF ONLY AROUND 15 MONTHS FROM THE TIME OF DIAGNOSIS HOUSTON, TX / ACCESS NEWSWIRE / NOVEMBER 17, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND PROVIDED A CORPORATE UPDATE. "AS WE HEAD INTO THE FINAL QUARTER OF THE YEAR, OUR MISSION REMAINS CENTERED ON DELIVERING MEANINGFUL DEVELOPMENTS FOR PATIENTS BATTLING BRAIN AND CNS CANCERS.

CNS PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

HOUSTON, TX / ACCESS NEWSWIRE / NOVEMBER 10, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THAT THREE ABSTRACTS HAVE BEEN SELECTED FOR POSTER PRESENTATION AT THE 2025 SNO ANNUAL MEETING BEING HELD NOVEMBER 19-23, 2025 IN HONOLULU, HI. DETAILS OF THE POSTER PRESENTATIONS ARE AS FOLLOWS: TITLE: ACTIVITY OF BERUBICIN AGAINST PEDIATRIC DIFFUSE MIDLINE GLIOMA (DMG) CELLS: PRELIMINARY DATA AND FUTURE POSSIBILITIES PRESENTER: SANDRA SILBERMAN, MD, PHD, CHIEF MEDICAL OFFICER OF CNS PHARMACEUTICALS ABSTRACT CODE: EXTH-133 DATE AND TIME: FRIDAY, NOVEMBER 21, 2025 AT 11:45 AM - 1:05 PM HST LOCATION: HAWAII CONVENTION CENTER, KAMEHAMEHA EXHIBIT HALL II & III TITLE: TPI 287, WHICH IN COMBINATION WITH BEVACIZUMAB (BEV) HAS SHOWN ACTIVITY IN PATIENTS WITH GLIOBLASTOMA (GBM) AFTER PRIOR THERAPY, WILL BE EVALUATED IN A PHASE 2 TRIAL AS WELL AS IN OTHER CNS DISEASES PRESENTER: SANDRA SILBERMAN, MD, PHD, CHIEF MEDICAL OFFICER OF CNS PHARMACEUTICALS ABSTRACT CODE: CTNI-70 DATE AND TIME: SATURDAY, NOVEMBER 22, 2025 AT 11:45 AM - 1:05 PM HST LOCATION: HAWAII CONVENTION CENTER, KAMEHAMEHA EXHIBIT HALL II & III TITLE: PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES PRESENTER: SANDRA SILBERMAN, MD, PHD, CHIEF MEDICAL OFFICER OF CNS PHARMACEUTICALS ABSTRACT CODE: CTNI-74 DATE AND TIME: SATURDAY, NOVEMBER 22, 2025 AT 11:30 AM - 12:45 PM HST LOCATION: HAWAII CONVENTION CENTER, KAMEHAMEHA EXHIBIT HALL II & III FOR MORE INFORMATION ABOUT THE EVENT, PLEASE VISIT THE MEETING WEBSITE.

CNS Pharmaceuticals, Inc.

CNSP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CNS Pharmaceuticals, Inc.

CNSP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CNSP